Five approved therapies, one shared access gate: US payers route every IgAN agent through the pharmacy benefit and condition coverage on biopsy, proteinuria, eGFR and RAS-blockade step-through.
Five therapies carry FDA approval for IgA nephropathy: targeted-release budesonide (Tarpeyo), sparsentan (Filspari), atrasentan (Vanrafia), iptacopan (Fabhalta) and sibeprenlimab (Voyxact). All are patient-administered and route through the Medicare Part D / commercial pharmacy benefit rather than the medical benefit. Four are oral; sibeprenlimab is a self-administered subcutaneous injection. That uniform routing makes prior-authorization criteria, not site-of-care, the decisive access lever.
Representative commercial and Part D policies gate coverage on biopsy-confirmed primary IgAN, an eGFR floor (generally ≥30 mL/min/1.73m²), a proteinuria threshold (often UPCR ≥0.8–1.5 g/g), and a documented trial of optimized renin-angiotensin blockade (increasingly with an SGLT2 inhibitor) before a disease-specific agent is covered; some plans additionally step-edit through budesonide. Sparsentan carries a REMS for hepatotoxicity monitoring that adds enrollment friction its REMS-free competitors avoid. Against this, the ICER 2026 IgA nephropathy assessment (CTAF review) frames value on working net-price estimates and the ESKD cost-avoidance case, while every agent's accelerated approval leaves confirmatory eGFR evidence as the outstanding question for durable formulary coverage.
US IgA nephropathy agent payer routing, PA gates and REMS — 2026
| Drug (Brand / INN) | Benefit Routing | Route | Representative PA Gate | REMS | Key Access Note |
|---|---|---|---|---|---|
| Tarpeyo (budesonide, targeted-release) | Medicare Part D / pharmacy benefit | Oral, 9-month course | Biopsy-confirmed IgAN; UPCR threshold; eGFR ≥30; RAS-blockade step-through | No | Full approval (NefIgArd eGFR data) eases coverage vs accelerated-only peers |
| Filspari (sparsentan) | Medicare Part D / pharmacy benefit | Oral, daily | Biopsy-confirmed IgAN; UPCR ≥1.0 g/g typical; eGFR ≥30; RAS-blockade step-through; some plans step-edit budesonide | Yes — hepatotoxicity | REMS enrollment adds friction vs REMS-free competitors |
| Vanrafia (atrasentan) | Medicare Part D / pharmacy benefit | Oral, daily | Biopsy-confirmed IgAN; UPCR threshold; eGFR ≥30; RAS-blockade step-through | No | Selective ET-A antagonist; REMS-free oral alternative to sparsentan |
| Fabhalta (iptacopan) | Medicare Part D / pharmacy benefit | Oral, twice daily | Biopsy-confirmed IgAN; UPCR threshold; eGFR ≥30; RAS-blockade step-through | No | Complement inhibitor — meningococcal vaccination required; PA criteria still forming |
| Voyxact (sibeprenlimab) | Medicare Part D / pharmacy benefit | SC, self-administered q4w | Biopsy-confirmed IgAN; UPCR threshold; eGFR ≥30; RAS-blockade step-through | No | Newest approval (2025); first-in-class APRIL inhibitor; PA criteria forming |
Sources: FDA Drugs@FDA (approval status, REMS and labeling); FDA/Travere Filspari REMS; representative commercial and Medicare Part D specialty pharmacy prior-authorization policies (2025–2026); ICER 2026 IgA nephropathy assessment (CTAF review); USRDS Annual Data Report (ESKD costs). Confirmatory-evidence context: PROTECT (PMID 37931634) and NefIgArd (PMID 37591292).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Representative commercial and Part D prior-authorization criteria by product • Biopsy-confirmation, eGFR floor and proteinuria (UPCR) entry thresholds • Required duration of optimized RAS blockade ± SGLT2i and any budesonide step-edit • Pharmacy-benefit (Part D) routing for all five patient-administered agents
Delivers
- • Sparsentan REMS hepatotoxicity monitoring requirements and enrollment burden • Comparison with REMS-free oral competitors (atrasentan, iptacopan, budesonide) • Practical impact on time-to-fill and prescriber uptake • Where REMS sits in payer step-edit logic
Delivers
- • ICER 2026 IgAN assessment and CTAF review: working net-price and cost-effectiveness estimates • ESKD cost-avoidance economics as the payer value frame • Accelerated-approval conditional-coverage risk pending confirmatory eGFR data • eGFR confirmatory readouts that could reset payer posture
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why prior-authorization criteria, not site-of-care, are the decisive access lever for all five patient-administered IgAN therapies.
- How UnitedHealthcare/Optum, CVS Caremark/Aetna and Cigna policies converge on the same biopsy, eGFR and proteinuria gates.
- How biopsy-confirmed IgAN, UPCR 0.8-1.5 g/g and eGFR ≥30 mL/min/1.73m² combine as the representative PA threshold.
- Why some plans additionally step-edit through budesonide before covering sparsentan, atrasentan, iptacopan or sibeprenlimab.
- Why four oral agents and one self-administered subcutaneous injection all route through Part D rather than the medical benefit.
- How Voyxact's q4w subcutaneous dosing still clears the same pharmacy-benefit routing as Tarpeyo's 9-month oral course.
- How the sparsentan hepatotoxicity REMS adds enrollment friction that atrasentan, iptacopan and budesonide competitors avoid.
- Why Tarpeyo's full approval on NefIgArd 2-year eGFR data eases coverage versus its accelerated-approval-only peers.
- How the ICER 2026 IgAN assessment and CTAF review frame value on working net-price and cost-effectiveness estimates.
- Why USRDS ESKD cost-avoidance economics, not list price alone, anchor the payer value case for all five agents.
- Why accelerated-approval agents carry confirmatory eGFR evidence as the outstanding question for durable formulary coverage.
- How PROTECT and NefIgArd 2-year eGFR readouts (PMID 37931634, PMID 37591292) could reset payer posture.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
US IgA nephropathy Payer & HTA is built from primary regulatory records (FDA Drugs@FDA, product labeling and REMS documentation), live commercial and Medicare Part D specialty-pharmacy coverage and prior-authorization policies, the ICER 2026 IgA nephropathy assessment, and USRDS ESKD cost data — not secondary summaries. Every access claim is checked against a live policy or regulatory record before inclusion.
Key sources: FDA Drugs@FDA and product labeling for approval status, routing and the sparsentan REMS; representative UnitedHealthcare/Optum, CVS Caremark/Aetna and Cigna specialty prior-authorization criteria; the ICER 2026 IgAN assessment and CTAF review; the USRDS Annual Data Report for ESKD cost-avoidance economics; and primary confirmatory-endpoint trial evidence — PROTECT 2-year eGFR (PMID 37931634) and NefIgArd 2-year eGFR (PMID 37591292).
- Confirmatory eGFR evidence verified against the PROTECT 2-year results, Lancet (PMID 37931634)
- Targeted-release budesonide eGFR confirmation verified against NefIgArd 2-year results, Lancet (PMID 37591292)
- Benefit routing, approval status and the sparsentan REMS verified against FDA Drugs@FDA and product labeling
- Prior-authorization criteria verified against current commercial and Medicare Part D specialty pharmacy coverage policies
- Cost-effectiveness framing verified against the ICER 2026 IgA nephropathy assessment (CTAF review)
Frequently asked questions
Commission this assessment
AXLRx delivers US IgA nephropathy payer and HTA intelligence built for market access, HEOR, and pricing teams navigating PA design, the Filspari REMS, Part D routing and the ICER 2026 assessment. Custom assessment in 72 hours.
Specify indication, payer focus (PA criteria, REMS, ICER), and commercial question.
AXLRx analyst confirms payer scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.